Get the Stockscreener App
8.94
21.30%
1.57
After Hours:
9.13
0.19
+2.13%
Karyopharm Therapeutics Inc stock is traded at $8.94, with a volume of 2.75M.
It is up +21.30% in the last 24 hours and up +9.09% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$7.37
Open:
$6.72
24h Volume:
2.75M
Relative Volume:
8.26
Market Cap:
$163.69M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.8115
EPS:
-11.016
Net Cash Flow:
$-102.89M
1W Performance:
+46.80%
1M Performance:
+9.09%
6M Performance:
+122.39%
1Y Performance:
+1.74%
1-Day Range:
$6.72
$9.9399
1-Week Range:
$5.90
$9.9399
52-Week Range:
$3.51
$10.38
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.94 | 134.95M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics Inc Shares Rise After Q4 2025 Results - AlphaStreet News
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Financial Challenges - GuruFocus
Karyopharm reports fourth quarter and full year 2025 financial results and highlights recent company progress - marketscreener.com
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations - Investing.com
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlig - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS - MarketBeat
Page not foundAirwhon - MarketBeat
Earnings call transcript: Karyopharm sees 11.8% revenue rise in Q4 2025 - Investing.com India
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations By Investing.com - Investing.com India
KPTI: Q4 revenue up, operating loss improved, pivotal phase 3 data in myelofibrosis due soon - TradingView
Karyopharm Therapeutics: Fourth Quarter Earnings Overview - Bitget
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-Market - ChartMill
KARYOPHARM THERAPEUTICS ($KPTI) Releases Q4 2025 Earnings - Quiver Quantitative
Karyopharm Therapeutics: Q4 Earnings Snapshot - wwltv.com
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Reports 2025 Financials and 2026 Outlook - Intellectia AI
Uncovering Potential: Karyopharm Therapeutics's Earnings Preview - Benzinga
Investment Report: Can Karyopharm Therapeutics Inc disrupt its industry2025 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Stock Market Recap: Can Karyopharm Therapeutics Inc disrupt its industryTrade Performance Summary & Risk Managed Investment Entry Signals - baoquankhu1.vn
Karyopharm Therapeutics (KPTI) Expected to Announce Earnings on Thursday - MarketBeat
Karyopharm Therapeutics (KPRX): Tiny Cancer Stock, Massive Drama – Is It Worth Your Money? - AD HOC NEWS
Cantor Fitzgerald Initiates Coverage on KPTI with Overweight Rat - GuruFocus
Cantor Fitzgerald initiates Karyopharm stock with Overweight rating By Investing.com - Investing.com South Africa
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Karyopharm
Cancer drug maker Karyopharm to detail 2025 results in Feb. 12 call - Stock Titan
Cantor Fitzgerald Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Cantor Fitzgerald initiates Karyopharm stock with Overweight rating - Investing.com India
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
FOMO Trade: How sensitive is Karyopharm Therapeutics Inc to inflationJuly 2025 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 110.2% in January - Defense World
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - MarketBeat
Abate, Karyopharm Therapeutics CAO, sells $351 in stock By Investing.com - Investing.com UK
Abate, Karyopharm Therapeutics CAO, sells $351 in stock - Investing.com
Myelofibrosis Clinical Trials Outlook: Competitive Intelligence, Regulatory Progress, Emerging Therapies, Mechanisms of Action, and Administration Pathways – DelveInsight - Barchart.com
Portfolio Update: mơ công an bắt xeQuarterly Earnings Report & Proven Capital Preservation Methods - baoquankhu1.vn
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving AverageHere's What Happened - MarketBeat
Can Karyopharm Unlock Xpovio's Growth In 2026 With Pivotal Myelofibrosis Data Ahead? - RTTNews
How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI) - Yahoo Finance
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock By Investing.com - Investing.com UK
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock - Investing.com
RBC Raises Price Target on Karyopharm Therapeutics to $23 From $19, Keeps Outperform Rating - marketscreener.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Spikes: Can Karyopharm Therapeutics Inc disrupt its industryDividend Hike & Verified Entry Point Signals - baoquankhu1.vn
Chart Watch: Will Karyopharm Therapeutics Inc outperform its industry peersJuly 2025 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Options Flow: Will Karyopharm Therapeutics Inc 25K0 stock rise with strong economyWeekly Risk Summary & Safe Entry Zone Tips - Bộ Nội Vụ
Layoff Watch: What margin trends mean for Karyopharm Therapeutics Inc stockWeekly Stock Analysis & Accurate Intraday Trading Signals - Bộ Nội Vụ
Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Establishment Labs Holdings (ESTA) - The Globe and Mail
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):